EconSight News
Top Companies in GenAI
The World of GenAI - Top Companies in Generative AI The World of GenAI - Top Companies in Generative AI The World of GenAI - Top Companies in Generative AI View animation full screen The world of GenAI in one chart – Alphabet leads Tencent and Baidu in world-class GenAI patents The chart shows all companies worldwide with at least four GenAI patents and their development over the past ten years. The colour coding makes clear that GenAI activity [...]
EconSight Gamechanger Model Portfolio doubles since launch
EconSight Gamechanger Model Portfolio doubles since launch EconSight Gamechanger Model Portfolio doubles since launch – outperforming MSCI World and Nasdaq 100 EconSight Gamechanger Model Portfolio with significant outperformance We’re proud to share a major milestone: the EconSight Gamechanger Model Portfolio has more than doubled in value (+134%) since its launch in January 2024. Over the same period, the MSCI World rose +41% and the Nasdaq 100 +55% - meaning our patent-based innovation approach has delivered a clear competitive edge and consistent alpha. This performance shows that patent-driven innovation metrics can reliably identify tomorrow’s market leaders. [...]
China Tech Focus in new 5-year plan
China technology focus in new 5-year plan for 2026-2030 China position in strategic technologies As part of the recommendations for the next five-year plan, China has outlined its technology priorities for the near future. The technologies themselves are not a big surprise. However, the documents and statements of the last few days reveal a stronger focus on innovation quality. From a patent perspective, this is understandable, which is why we are showing here where China stands in these focus technologies compared to the US and Europe in terms of world-class patents. China is a leader [...]
EconSight ETFs reach 1 billion in assets under management
From Insight to Impact: USD 1 Billion in EconSight Technologies - based ETF Assets We’re proud to announce that the EconSight technology classification based ETFs we have developed with our index clients have surpassed USD 1 billion in assets under management! This milestone proves that patent based technologies intelligence isn’t just for R&D — it’s a powerful tool for identifying and investing in the world’s most innovative companies. In partnership with our clients, we’ve built indexes that underlie ETFs that capture innovation across Digitization, Sustainability, and Security. Artificial Intelligence Quantum Computing Metaverse Battery Technologies Defense [...]
Genmab after Merus acquisition
Genmab after Merus acquisition Genmab strengthens position among global immunotherapy leaders with Merus acquisition From a patent perspective, the acquisition represents a highly strategic move. Genmab now advances to position 25 among the leading immunotherapy companies, measured by the number of world-class patents. This transaction further strengthens Genmab’s already robust market position. Roche and Bristol Myers Squibb remain industry leaders. When focusing on specialized immunotherapy companies—those with more than half of their patents in this field—the acquisition elevates Genmab into the global top 5, ranking just behind Incyte and BioNTech. For [...]
Q&A with EconSight and STOXX
Thematic Investing - Q&A with EconSight and STOXX Q&A with EconSight and STOXX: Navigating the patents landscape in emerging AI technologies In this behind-the-scenes look, you can learn more about how EconSight and STOXX recently teamed up to develop two indices targeting leading companies in specific segments of AI adoption: STOXX Global AI Infrastructure and STOXX Global AI Adopters and Applications. The two indices form the basis for corresponding ETFs from BlackRock iShares. Read the STOXX Blog (external link)
BioNTech and CureVac after takeover
BioNTech and CureVac after takeover BioNTech among top players in mRNA and vaccines after CureVac acquisition The planned acquisition of CureVac announced yesterday makes strategic sense for BioNTech. BioNTech justifies the acquisition with its improved positioning in mRNA technologies. EconSight can confirm this from a patent perspective. In terms of world-class patents in mRNA technologies, BioNTech ranks third after the CureVac acquisition with 141 world-class patents, behind Moderna (252 world-class patents) and 10x Genomics (166 world-class patents). Without a world-class focus, i.e. based [...]
Big Tech Shootout – USA vs China Part II
Big Tech Shootout USA vs China - Pt. 2 - Advanced Digital Technologies The chart shows the technological activities as world shares held by the company in each technology. World share is defined as the share of company world class patents in total global patents in a technology. A bubble position to the right shows a high world share compared to the other companies. US Top-5 tech companies vs. Chinese Top-5 tech companies – advanced digital technologies Microsoft top in a majority of [...]
Big Tech Shootout – USA vs China
Big Tech Shootout USA vs China - Pt. 1 - Human-Machine-Interface Technologies The chart shows the technological activities as world shares held by the company in each technology. World share is defined as the share of company world class patents in total global patents in a technology. A bubble position to the right shows a high world share compared to the other companies. US Top-5 tech companies vs. Chinese Top-5 tech companies – human-machine interface technologies In public debate, big tech companies are often portrayed as a [...]
MarketVector Quantum Computing Index based on EconSight patent insights
MarketVector Quantum Computing Index based on EconSight patent insights MarketVector's Quantum Computing Index based on EconSight’s advanced technology and patent expertise EconSight provided the patent data for MarketVector's Global Quantum Leaders Total Return Net Index. The index is made up of companies primarily focused on the development of quantum computing technology or are leaders in ownership of quantum computing related patents. EconSight has supplied the underlying quantum computing patent technology data with a focus on owners of world-class patents in the technology. This is the basis for the first diversified investment [...]
China Technology Monitor
China Technology Monitor China on its way to becoming the leading technology nation One of the reasons why China is taking such an aggressive stance in the trade conflict with the US is the significant progress it has made in strategically relevant technologies in recent years. The transition from high-quality production to high-quality research and development is a relatively recent development in China, which first became apparent around 2015. Ten years later, in 2025, China is the leader in many cutting-edge technologies or ranks second behind the US. EconSight first highlighted this development in its [...]
EconSight QuantumBasel cooperation
EconSight and QuantumBasel – strategic cooperation QuantumBasel and EconSight form strategic partnership to overcome the current limitations of patent analysis QuantumBasel and EconSight are pooling their expertise to take the analysis of highly complex patent data to a new level with the help of AI and quantum computing. The aim: to make hidden correlations in fields of innovation visible and strengthen strategic decisions with data support. Why are patents so important for innovation? Kai Gramke, CEO EconSight: Patents are considered a reliable indicator of a company's innovative activity. The number of patents is growing [...]